FY25 paylines drop to 4th percentile—a historic low—as NCI braces for Trump’s FY26 budget cuts

Population-based cancer surveillance is a national treasure at risk

There is a silent crisis in cancer research that underpins nearly all aspects of the work we do to combat this disease.

September 26, 2025

By Eric B. Durbin, Karen L. Knight, Betsy Kohler and Sarah Nash

Bhattacharya: New grant review criterion is “not political”

NIH’s new “unified grant funding policy,” is “not political,” NIH Director Jay Bhattacharya said during his remarks at Research!America’s annual National Health Research Forum Sept. 17.

September 26, 2025

Vol.51 No.35

By Jacquelyn Cobb

Funding Opportunities

Project Purple announces research grant to sustain pancreatic cancer studies that have been disrupted by federal funding policy changes

Project Purple, a national nonprofit dedicated to empowering the fight against pancreatic cancer, is launching the Pancreatic Cancer Research Recovery Support Grant. The initiative provides up to two years of bridge or rescue funding for promising pancreatic cancer research projects that were disrupted due to administrative funding policy changes at major federal agencies such as the NIH, the Department of Defense, or the National Science Foundation.

September 26, 2025

Vol.51 No.35

NCI

Anthony G. Letai to be named NCI director
The Dana-Farber and Harvard physician-scientist is an inspired choice, colleagues say

Anthony G. Letai, a physician-scientist at Harvard Medical School and Dana-Farber Cancer Institute whose research is focused on apoptosis and functional diagnostics, has been tapped by the Trump administration to become the 18th director of the National Cancer Institute.

September 25, 2025

Vol.51 No.35

By Claire Marie Porter and Paul Goldberg

Podcast

Congress seems to have NCI’s back—is cautious optimism warranted? Two former directors say yes.

With the fiscal year drawing to a close, grant funding from NCI is picking up speed, offering a glimmer of hope to cancer researchers who are beginning to feel cautiously optimistic about the road ahead.

September 24, 2025

NCI is “really, really sturdy” and won’t break, former directors Ned Sharpless and Kim Rathmell say at UNC Lineberger symposium

Grants are flowing out of NCI again to beat the fiscal-year end deadline and some cancer researchers are starting to feel cautiously optimistic about the future.

September 19, 2025

Vol.51 No.34

By Paul Goldberg

FY25 paylines drop to 4th percentile—a historic low—as NCI braces for Trump’s FY26 budget cuts

YOU MAY BE INTERESTED IN

Population-based cancer surveillance is a national treasure at risk

Bhattacharya: New grant review criterion is “not political”

Project Purple announces research grant to sustain pancreatic cancer studies that have been disrupted by federal funding policy changes

Anthony G. Letai to be named NCI director
The Dana-Farber and Harvard physician-scientist is an inspired choice, colleagues say

Congress seems to have NCI’s back—is cautious optimism warranted? Two former directors say yes.

NCI is “really, really sturdy” and won’t break, former directors Ned Sharpless and Kim Rathmell say at UNC Lineberger symposium

Renew today!

Subscriber content

Never miss an issue!

Login

FY25 paylines drop to 4th percentile—a historic low—as NCI braces for Trump’s FY26 budget cuts

YOU MAY BE INTERESTED IN

Population-based cancer surveillance is a national treasure at risk

Bhattacharya: New grant review criterion is “not political”

Project Purple announces research grant to sustain pancreatic cancer studies that have been disrupted by federal funding policy changes

Anthony G. Letai to be named NCI directorThe Dana-Farber and Harvard physician-scientist is an inspired choice, colleagues say

Congress seems to have NCI’s back—is cautious optimism warranted? Two former directors say yes.

NCI is “really, really sturdy” and won’t break, former directors Ned Sharpless and Kim Rathmell say at UNC Lineberger symposium

Never miss an issue!

Login

Anthony G. Letai to be named NCI director
The Dana-Farber and Harvard physician-scientist is an inspired choice, colleagues say